LIPO vs. BLUE, PEPG, IPSC, ATRA, ARTV, QNCX, AVTX, NRXP, PMVP, and MRSN
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include bluebird bio (BLUE), PepGen (PEPG), Century Therapeutics (IPSC), Atara Biotherapeutics (ATRA), Artiva Biotherapeutics (ARTV), Quince Therapeutics (QNCX), Avalo Therapeutics (AVTX), NRx Pharmaceuticals (NRXP), PMV Pharmaceuticals (PMVP), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry.
Lipella Pharmaceuticals vs. Its Competitors
bluebird bio (NASDAQ:BLUE) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than bluebird bio. MarketBeat recorded 2 mentions for Lipella Pharmaceuticals and 1 mentions for bluebird bio. bluebird bio's average media sentiment score of 1.44 beat Lipella Pharmaceuticals' score of 1.06 indicating that bluebird bio is being referred to more favorably in the media.
bluebird bio presently has a consensus price target of $44.60, suggesting a potential upside of 797.38%. Given bluebird bio's stronger consensus rating and higher probable upside, equities analysts clearly believe bluebird bio is more favorable than Lipella Pharmaceuticals.
bluebird bio received 1040 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 70.34% of users gave bluebird bio an outperform vote.
Lipella Pharmaceuticals has lower revenue, but higher earnings than bluebird bio. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
87.4% of bluebird bio shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 1.4% of bluebird bio shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
bluebird bio has a net margin of -565.74% compared to Lipella Pharmaceuticals' net margin of -882.82%. Lipella Pharmaceuticals' return on equity of -192.33% beat bluebird bio's return on equity.
bluebird bio has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
Summary
bluebird bio beats Lipella Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LIPO) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy LIPO Stock Free LIPO Stock Alerts